
9.92 Delayed Data As of Jul 01 | ![]() Today’s Change | 4.98 Today|||52-Week Range 65.33 | -40.53% Year-to-Date |
The 10 analysts offering 12-month price forecasts for BridgeBio Pharma Inc have a median target of 23.50, with a high estimate of 32.00 and a low estimate of 13.00. The median estimate represents a +136.90% increase from the last price of 9.92.
The current consensus among 10 polled investment analysts is to Buy stock in BridgeBio Pharma Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.